Company intelligence / Profile preview

CXOrchestra

New Hope, Pennsylvania, United States

Ownership: Private
Employees: ~70
Development stage: Other

Overview

Orchestra BioMed is advancing two late-stage flagship technologies—Virtue SAB, a drug/device combination delivering sirolimus during angioplasty without permanent implants, and BackBeat CNT™, a bioelectronic therapy targeting hypertension. Both are investigational and not yet commercially approved. Virtue SAB is entering pivotal trials in partnership with Terumo Corporation; BackBeat CNT™ has collaboration agreements with Medtronic for development in pacemaker-indicated patients.

Therapeutic areas: Cardiovascular
Modalities: Drug/device combination productBioelectronic therapyMedical device
Industry: Therapeutic Medical Devices

Partnerships

Terumo Corporation/Terumo Medical Corporation – strategic partnership on Virtue SABMedtronic – collaboration on AVIM/BackBeat CNT™ for hypertension in pacemaker patients

Beyond the preview

Go deeper on CXOrchestra.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CXOrchestra.

Explore the full profile